Drug Trial Radar · NCT07775391
Phase Ⅰ/Ⅱa Trial Evaluating Intravenous hUC-MSCs Injection for Safety, Tolerability and Efficacy in Patients With POI
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
59
Planned (sponsor's estimate)
Start
Aug 3, 2026
Primary completion
Sep 30, 2028
Study completion Aug 2, 2029
Sponsor
- Lead sponsor
- Shenzhen Wingor Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/IIa clinical study evaluating the safety, tolerability and efficacy of intravenously administered human umbilical cord mesenchymal stem cell (hUC-MSCs) injection in patients with premature ovarian insufficiency (POI). The primary objective of the Phase I dose-escalation stage is to assess the safety and tolerability of intravenous infusion of hUC-MSCs injection for the treatment of POI, and to determine the recommended phase II dose (RP2D) for the Phase IIa clinical trial. The primary objective of the Phase IIa dose-expansion stage is to evaluate the efficacy of intravenous infusion of hUC-MSCs injection in POI treatment, and to generate data to support pivotal/confirmatory clinical trials.
Conditions
- Premature Ovarian Insufficiency
Interventions
hUC-MSCs Injection (Phase I)Drug
hUC-MSCs Injection, administered via intravenous infusion as a single dose on D0.
hUC-MSCs Injection (Phase IIa)Drug
hUC-MSCs Injection, 3 infusions in total, dosing interval ≥7 days.
PlaceboDrug
3 infusions in total, dosing interval ≥7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I : Incidence and number of subjects with treatment-emergent adverse events and serious adverse events.Time frame: 48 weeks
- Phase II :FSHTime frame: at Week 24 post-treatment
- Phase II :E2Time frame: at Week 24 post-treatment
- Phase II :AMHTime frame: at Week 24 post-treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.